Page 11 - சேர்க்கை மேலாண்மை மென்பொருள் சந்தை பிராந்திய News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சேர்க்கை மேலாண்மை மென்பொருள் சந்தை பிராந்திய. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சேர்க்கை மேலாண்மை மென்பொருள் சந்தை பிராந்திய Today - Breaking & Trending Today

Press Release : Affimed Announces Presentations at the AACR Annual Meeting 2021

Message :
Required fields
AFM24 preclinical in vivo data will be presented as a poster
Data on AFM13 in combination with adoptive NK cells will be presented
during a Major Symposium
Heidelberg, Germany, March 10, 2021 Affimed N.V. (Nasdaq: AFMD), a
clinical-stage immuno-oncology company committed to giving patients back
their innate ability to fight cancer, announced today that preclinical
anti-tumor efficacy in vivo data from its innate cell engager (ICE(R) )
AFM24 have been accepted for e-poster presentation at the American
Association for Cancer Research (AACR) Virtual Annual Meeting I, being
held on April 10-15.
In addition, early data from a Phase 1 study evaluating AFM13 preloaded ....

United States , New York , Baden Wuberg , Cassandra Choe Juliak , Affimednv Affimed , Gabriele Hintzen , Jens Pahl , Sheena Pinto , Torsten Haneke , Uwe Reusch , Andreas Harstrick , Katy Rezvani , Joachim Koch , Arndt Schottelius , Mary Beth Sandin , Christian Breunig , Wolfgang Fischer , Panel Session , American Association For Cancer Research , University Of Texas Md Anderson Cancer Center , Md Anderson Cancer Center , Department Of Stem Cell Transplantation , Cancer Research Professor Of Medicine , Translational Research , Major Symposium , Cancer Research ,

Summer camps prepare for incoming campers with precautions

Summer camps are expecting higher enrollment numbers this year as many were forced to shut down last summer due to COVID-19. ....

Jim Fitzgerald , Jill Wilke , Turkey Hill Ranch Bible , Wonderland Camp , Rocky Mount , Turkey Hill Ranch , Summer Camp , ஜிம் ஃபிட்ஸ்‌ஜெரல்ட் , ஜில் வில்கே , வான்கோழி மலை பண்ணையில் திருவிவிலியம் , அதிசயம் முகாம் , பாறை ஏற்ற , வான்கோழி மலை பண்ணையில் , கோடை முகாம் , சர்வதேச பரவல் ,

Rigel Completes Patient Enrollment In Phase 2 Trial To Evaluate Fostamatinib In COVID-19 Patients

Rigel Completes Patient Enrollment In Phase 2 Trial To Evaluate Fostamatinib In COVID-19 Patients
WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals, Inc. (RIGL) announced the completion of patient enrollment in a multi-center phase 2 clinical trial to evaluate the safety of fostamatinib, the company s oral spleen tyrosine kinase inhibitor, for the treatment of hospitalized COVID-19 patients. Treatment will be administered orally twice daily for 14 days. There will be a follow-up period to day 60.
Fostamatinib is marketed in the U.S. as TAVALISSE tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia.
Rigel expects to report topline data from the clinical trial in April 2021. ....

United States , Rigel Pharmaceuticals Inc , Co Vid , ஒன்றுபட்டது மாநிலங்களில் , கடுமையான மருந்துகள் இன்க் , இணை வித் ,

Six Nations: Italy make 5 changes for Wales - English

(ANSA) - ROME, MAR 11 - Italy coach Franco Smith has made five changes to the Italy starting line-up to face Wales at the Olimpico on Saturday compared to the team that went down 48-10 at home to Ireland two weeks ago.
    The outside trio will be made up of Trulla at fullback with Ioane and Bellini on the wings.
    The centre combo of Brex and Canna will make their third straight start.
    Garbisi and Varney will be behind the scrum.
    The back row has been confirmed with Lamaro at number eight joined by Negri and Meyer.
    Sisi will be flanked in the second row by Cannone who makes his starting return. ....

Franco Smith , பிராங்கோ ஸ்மித் ,

Transgene Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Combination With Avelumab Versus Avelumab Monotherapy in Patients With HPV16-positive Anogenital Cancers

Transgene Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Combination With Avelumab Versus Avelumab Monotherapy in Patients With HPV16-positive Anogenital Cancers
-
Trial will focus on patients without liver metastases, based on encouraging data in Phase Ib/II study
-
Trial targets indications where clinical outcomes can be improved versus standard therapeutic options and immune checkpoint inhibitors ( ICIs )
-
Continued clinical collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to conduct the expanded Phase II study
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces the expansion of a randomized, controlled study with TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital tumors (NCT: 03260023) ....

Distrito Federal , United States , United Kingdom , Lucie Larguier , Christophe Le Tourneau , Le Tourneau , Transgene Euronext , Sylvie Berrebi , Maud Brandely , Citigate Dewe Rogerson , Head Of The Department Drug Development , Information Center Statistics , Curie Institute , Merck Kga , Pfizer Inc , Merck Kgaa , Corporate Communications , Information Center Prevention , American Cancer Society , Euronext Paris , Drug Development , Principal Investigator , Chief Medical Officer , Positive Cancers , Artificial Intelligence , Approved Indications ,